Physician profile
Eric J Hall
NPI 1396798971
$4,259.57
in general payments reported to CMS, 2019-2025
17 companies · $644 in 2025
The $644 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $15.78 · 2021: $176 · 2022: $848 · 2023: $1,078 · 2024: $1,301 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,771 · Entertainment: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,770.99 |
| Entertainment | $251.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,371.31 | 2019-2025 | Rocklatan, Rhopressa, Eysuvis |
| Johnson & Johnson Vision Care, INC. | $611.14 | 2019-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $364.90 | 2019-2024 | Cequa |
| Rxsight INC | $282.17 | 2023-2024 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece |
| Optos, INC. | $251.95 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $236.99 | 2023-2025 | Miebo, Xiidra, Infuse |
| Allergan, INC. | $197.10 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $176.18 | 2024 | Xdemvy |
| Oyster Point Pharma, INC. | $140.30 | 2022 | |
| Abbvie INC. | $122.53 | 2022-2025 | |
| Biotissue Holdings INC. | $104.96 | 2025 | |
| Novartis Pharmaceuticals Corporation | $95.89 | 2019-2023 | |
| Abb Con-Cise Optical Group LLC | $85.24 | 2021-2025 | Contact Lens, Spectacle Lenses |
| Coopervision INC. | $73.70 | 2019-2024 | Myday Contact Lens |
| Dompe US, INC. | $65.21 | 2024-2025 | Oxervate |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $45.00 | 2023 | |
| Lombart Brothers, INC. | $35.00 | 2023 | Opd-III |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.